A robust lentiviral pseudotype neutralisation assay for in-field serosurveillance of rabies and lyssaviruses in Africa

Vaccine

Volumn 27, Issue 51, 2009, Pages 7178-7186

  Wright, Edward ^a   McNabb, Suzanne ^b,c   Goddard, Trudy ^d   Horton, Daniel L ^d,e   Lembo, Tiziana ^c,g   Nel, Louis H ^f   Weiss, Robin A ^a   Cleaveland, Sarah ^c,g   Fooks, Anthony R ^d  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY OF EDINBURGH   (United Kingdom)

^c TANZANIA WILDLIFE RESEARCH INSTITUTE   (Tanzania)

^d VETERINARY LABORATORIES AGENCY   (United Kingdom)

^e Department of Veterinary Medicine ^*  (United Kingdom)

^f UNIVERSITY OF PRETORIA   (South Africa)

^g UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

Africa; Lyssavirus; Pseudotype; Rabies virus

Indexed keywords

BETA GALACTOSIDASE; GLYCOPROTEIN; KENNEL COUGH VACCINE; LENTIVIRUS VECTOR; RABIES IMMUNOGLOBULIN; VIRUS ENVELOPE PROTEIN;

AFRICA; ANTIBODY TITER; ARTICLE; CONTROLLED STUDY; EMBRYO; FEMALE; FREEZING; GENE SEQUENCE; HUMAN; HUMAN CELL; NONHUMAN; NUCLEOTIDE SEQUENCE; PATHOGENESIS; PRIORITY JOURNAL; RABIES; RABIES VIRUS; REPORTER GENE; ROOM TEMPERATURE; SENSITIVITY AND SPECIFICITY; SEROCONVERSION; SERODIAGNOSIS; SEROPREVALENCE; SINGLE DRUG DOSE; VACCINATION;

ANIMALS; ANTIBODIES, VIRAL; DOG DISEASES; DOGS; FEMALE; LENTIVIRUS; LYSSAVIRUS; MALE; NEUTRALIZATION TESTS; RABIES; RABIES VACCINES; RABIES VIRUS; SENSITIVITY AND SPECIFICITY; SEROEPIDEMIOLOGIC STUDIES; TANZANIA; VIRAL ENVELOPE PROTEINS;

EID: 71549143159     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2009.09.024     Document Type: Article

References (40)

1. Dodet B. Preventing the incurable: Asian rabies experts advocate rabies control. Vaccine 24 16 (2006) 3045-3049
2. Knobel D.L., Cleaveland S., Coleman P.G., Fevre E.M., Meltzer M.I., Miranda M.E., et al. Re-evaluating the burden of rabies in Africa and Asia. Bull World Health Organ 83 5 (2005) 360-368
3. Si H., Guo Z.M., Hao Y.T., Liu Y.G., Zhang D.M., Rao S.Q., et al. Rabies trend in China (1990-2007) and post-exposure prophylaxis in the Guangdong province. BMC Infect Dis 8 (2008) 113
4. Blanton J.D., Hanlon C.A., and Rupprecht C.E. Rabies surveillance in the United States during 2006. J Am Vet Med Assoc 231 4 (2007) 540-556
5. Fooks A. The challenge of new and emerging lyssaviruses. Expert Rev Vaccines 3 4 (2004) 333-336
6. Arai Y.T., Kuzmin I.V., Kameoka Y., and Botvinkin A.D. New lyssavirus genotype from the Lesser mouse-eared bat (Myotis blythi), Kyrghyzstan. Emerg Infect Dis 9 3 (2003) 333-337
7. Botvinkin A.D., Poleschuk E.M., Kuzmin I.V., Borisova T.I., Gazaryan S.V., Yager P., et al. Novel lyssaviruses isolated from bats in Russia. Emerg Infect Dis 9 12 (2003) 1623-1625
8. Kuzmin I.V., Orciari L.A., Arai Y.T., Smith J.S., Hanlon C.A., Kameoka Y., et al. Bat lyssaviruses (Aravan and Khujand) from Central Asia: phylogenetic relationships according to N, P and G gene sequences. Virus Res 97 2 (2003) 65-79
9. Markotter W., Kuzmin I., Rupprecht C.E., and Nel L.H. Phylogeny of Lagos bat virus: challenges for lyssavirus taxonomy. Virus Res 135 1 (2008) 10-21
10. Velasco-Villa A., Messenger S.L., Orciari L.A., Niezgoda M., Blanton J.D., Fukagawa C., et al. New rabies virus variant in Mexican immigrant. Emerg Infect Dis 14 12 (2008) 1906-1908
11. Nel L.H., and Rupprecht C.E. Emergence of lyssaviruses in the Old World: the case of Africa. Curr Top Microbiol Immunol 315 (2007) 161-193
12. Hayman D.T., Fooks A.R., Horton D., Suu-Ire R., Breed A.C., Cunningham A.A., et al. Antibodies against Lagos bat virus in megachiroptera from West Africa. Emerg Infect Dis 14 6 (2008) 926-928
13. Kuzmin I.V., Niezgoda M., Franka R., Agwanda B., Markotter W., Beagley J.C., et al. Lagos bat virus in Kenya. J Clin Microbiol 46 4 (2008) 1451-1461
14. Cleaveland S. Epidemiology and control of rabies. The growing problem of rabies in Africa. Trans R Soc Trop Med Hyg 92 March-April (2) (1998) 131-134 [Royal Society of Tropical Medicine and Hygiene meeting at Manson House, London, 20 March 1997]
15. Hampson K., Dobson A., Kaare M., Dushoff J., Magoto M., Sindoya E., et al. Rabies exposures, post-exposure prophylaxis and deaths in a region of endemic canine rabies. PLoS Negl Trop Dis 2 11 (2008) e339
16. Hampson K. The 9th SEARG meeting in Gaborone, Botswana. In: Taylor L. (Ed). Rabid Bytes (2008), Alliance for Rabies Control p. 5
17. Anonymous. WHO Expert Consultation on Rabies. WHO Technical Report Series; 2005. p. 931.
18. Dodet B, Fooks AR, Muller T, Tordo N (eds). Towards the Elimination of Rabies in Eurasia. OIE Publications; 2008.
19. Cliquet F., Aubert M., and Sagne L. Development of a fluorescent antibody virus neutralisation test (FAVN test) for the quantitation of rabies-neutralising antibody. J Immunol Methods 212 1 (1998) 79-87
20. Smith J.S., Yager P.A., and Baer G.M. A rapid reproducible test for determining rabies neutralizing antibody. Bull World Health Organ 48 5 (1973) 535-541
21. Cliquet F., McElhinney L.M., Servat A., Boucher J.M., Lowings J.P., Goddard T., et al. Development of a qualitative indirect ELISA for the measurement of rabies virus-specific antibodies from vaccinated dogs and cats. J Virol Methods 117 1 (2004) 1-8
22. Brookes S.M., Parsons G., Johnson N., McElhinney L.M., and Fooks A.R. Rabies human diploid cell vaccine elicits cross-neutralising and cross-protecting immune responses against European and Australian bat lyssaviruses. Vaccine 23 32 (2005) 4101-4109
23. Khawplod P., Inoue K., Shoji Y., Wilde H., Ubol S., Nishizono A., et al. A novel rapid fluorescent focus inhibition test for rabies virus using a recombinant rabies virus visualizing a green fluorescent protein. J Virol Methods 125 1 (2005) 35-40
24. Wright E., Temperton N.J., Marston D.A., McElhinney L.M., Fooks A.R., and Weiss R.A. Investigating antibody neutralization of lyssaviruses using lentiviral pseudotypes: a cross-species comparison. J Gen Virol 89 Pt 9 (2008) 2204-2213
25. DuBridge R.B., Tang P., Hsia H.C., Leong P.M., Miller J.H., and Calos M.P. Analysis of mutation in human cells by using an Epstein-Barr virus shuttle system. Mol Cell Biol 7 1 (1987) 379-387
26. Stoker M., and Macpherson I. Syrian hamster fibroblast cell line BHK21 and its derivatives. Nature 203 (1964) 1355-1357
27. Soda Y., Shimizu N., Jinno A., Liu H.Y., Kanbe K., Kitamura T., et al. Establishment of a new system for determination of coreceptor usages of HIV based on the human glioma NP-2 cell line. Biochem Biophys Res Commun 258 2 (1999) 313-321
28. Helseth E., Kowalski M., Gabuzda D., Olshevsky U., Haseltine W., and Sodroski J. Rapid complementation assays measuring replicative potential of human immunodeficiency virus type 1 envelope glycoprotein mutants. J Virol 64 5 (1990) 2416-2420
29. Thompson J.D., Higgins D.G., and Gibson T.J. CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice. Nucleic Acids Res 22 22 (1994) 4673-4680
30. Page R.D. TreeView: an application to display phylogenetic trees on personal computers. Comput Appl Biosci 12 4 (1996) 357-358
31. Ferry N., Duplessis O., Houssin D., Danos O., and Heard J.M. Retroviral-mediated gene transfer into hepatocytes in vivo. Proc Natl Acad Sci USA 88 19 (1991) 8377-8381
32. Rupprecht C.E., Hanlon C.A., and Slate D. Control and prevention of rabies in animals: paradigm shifts. Dev Biol (Basel) 125 (2006) 103-111
33. Windiyaningsih C., Wilde H., Meslin F.X., Suroso T., and Widarso H.S. The rabies epidemic on Flores Island, Indonesia (1998-2003). J Med Assoc Thai 87 11 (2004) 1389-1393
34. Belotto A.J. The Pan American Health Organization (PAHO) role in the control of rabies in Latin America. Dev Biol (Basel) 119 (2004) 213-216
35. Cleaveland S., Kaare M., Tiringa P., Mlengeya T., and Barrat J. A dog rabies vaccination campaign in rural Africa: impact on the incidence of dog rabies and human dog-bite injuries. Vaccine 21 17-18 (2003) 1965-1973
36. Kaare M., Lembo T., Hampson K., Ernest E., Estes A., Mentzel C., et al. Rabies control in rural Africa: evaluating strategies for effective domestic dog vaccination. Vaccine 27 1 (2009) 152-160
37. Hsu M., Zhang J., Flint M., Logvinoff C., Cheng-Mayer C., Rice C.M., et al. Hepatitis C virus glycoproteins mediate pH-dependent cell entry of pseudotyped retroviral particles. Proc Natl Acad Sci USA 100 12 (2003) 7271-7276
38. Temperton N.J., Chan P.K., Simmons G., Zambon M.C., Tedder R.S., Takeuchi Y., et al. Longitudinally profiling neutralizing antibody response to SARS coronavirus with pseudotypes. Emerg Infect Dis 11 3 (2005) 411-416
39. Temperton N.J., Hoschler K., Major D., Nicolson C., Manvell R., Hien V.M., et al. A sensitive retroviral pseudotype assay for influenza H5N1-neutralizing antibodies. Influenza Resp Viruses 1 3 (2007) 105-112
40. Wool-Lewis R.J., and Bates P. Characterization of Ebola virus entry by using pseudotyped viruses: identification of receptor-deficient cell lines. J Virol 72 4 (1998) 3155-3160